Ultragenyx Pharmaceutical Inc.
RARENASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $1.55B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $12.73$39.89
- Volume (live)
- -
- Avg. volume (3M)
- 5.33M
Ultragenyx Pharmaceutical (RARE) Stock Price & Financial Analysis
Ultragenyx Pharmaceutical Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $14.44 - $15.21 |
|---|---|
| 52-Week High | $39.89 |
| 52-Week Low | $12.73 |
| Open | $15.11 |
| Volume (last close) | 2.92M |
| Average Volume (3M) | 5.33M |
| Revenue (TTM) | 716.93M |
|---|---|
| Net Income (TTM) | -586.41M |
| Free Cash Flow (TTM) | -489.00M |
| EPS (TTM) | −$5.83 |
| Profit Margin | -81.79% |
| Operating Margin | -73.77% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 1.55B |
|---|---|
| Shares Outstanding | 101.90M |
| Price to Sales (P/S) | 2.16 |
| Price to Book (P/B) | -5.44 |
| EV/EBITDA | -5.55 |
| 50-Day MA | $19.45 |
|---|---|
| 200-Day MA | $23.33 |
| 1-Year Change | −53.52% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Ultragenyx Pharmaceutical at a Glance
As of the Oct 16, 2026 close, Ultragenyx Pharmaceutical (RARE) has a market capitalization of $1.55B. The stock trades at 2.2× sales. Over the trailing twelve months it lost $586.41M on revenue of $716.93M and burned $489.00M of free cash flow. Revenue grew 17.5% year over year.
As of its latest reported balance sheet, it holds $125.00M in cash and securities against $1.20B of debt, a net debt position of $1.08B.
Ultragenyx Pharmaceutical does not currently pay a dividend.
The share price is down 53.5% over the past year. At $14.54 (the Oct 16, 2026 close) it sits near the bottom of its 52-week range of $12.73 to $39.89, below its 200-day moving average of $23.33.
Based on 24 professional analyst ratings from the past 90 days, the consensus is Hold with an average price target of $27.85, 91.5% above the Oct 16, 2026 close.
Frequently Asked Questions About Ultragenyx Pharmaceutical
What is the current stock price for RARE?
As of the Oct 16, 2026 close, RARE stock trades at $14.54. The 52-week range is $12.73–$39.89, with a day range of $14.44–$15.21.
What is the P/E ratio for RARE?
The P/E ratio (Price-to-Earnings) for RARE is shown in the Key Statistics section. This valuation metric helps compare Ultragenyx Pharmaceutical Inc. to industry peers.
Does RARE pay dividends?
Ultragenyx Pharmaceutical does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for RARE?
Based on ratings from 24 professional analysts over the last 90 days, the consensus for RARE is Hold. The average 12-month price target is $27.85, a 91.5% upside from the Oct 16, 2026 close of $14.54.
What is the market cap of RARE?
As of the Oct 16, 2026 close, Ultragenyx Pharmaceutical's market capitalization is $1.48B, classifying it as a small-cap company. Ultragenyx Pharmaceutical operates in the Healthcare sector within the Biotechnology industry.